Intensity Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Intensity Therapeutics, Inc. (NASDAQ: INTS) is a late-stage clinical biotechnology company focused on localized cancer reduction and subsequent anti-cancer immune activation. The company's proprietary DfuseRx discovery platform designs patented anti-cancer product candidates that combine active cytotoxic agents with amphiphilic molecules to facilitate deep tumor penetration and cell diffusion. Its lead product candidate, INT230-6, is a single-vial formulation of cisplatin, vinblastine, and the amphiphilic molecule SHAO. INT230-6 is designed for direct intratumoral injection, inducing local tumor cell death and releasing a bolus of neoantigens that trigger a systemic, immune-mediated anti-tumor response.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the company's lead proprietary investigational product candidate, INT230-6, which is designed for direct intratumoral injection to kill tumors and increase immune system recognition of cancers.
Expected impact: Establish clinical efficacy and safety to achieve regulatory approvals and commercialization.
Managing operational expenses and pausing certain clinical trial enrollments (such as the INVINCIBLE-3 study) to align cash burn with available resources and extend the operating runway.
Expected impact: Extends the cash runway into the second quarter of 2027 and reduces near-term financing pressures.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Evaluating the combination of INT230-6 and Keytruda (pembrolizumab) in patients with advanced solid malignancies.
Terms: Merck provides Keytruda for the clinical study.
Evaluating the safety and efficacy of INT230-6 in combination with Yervoy (ipilimumab) in patients with solid tumors.
Terms: Bristol Myers Squibb supplies Yervoy for the study, while Intensity sponsors and conducts the trial.
Conducting the Phase 2 randomized INVINCIBLE-4 clinical trial in early-stage breast cancer in Europe.
Terms: Collaborative research and trial execution framework.